Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.500-1.580 for the period, compared to the consensus estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research started coverage on Repligen in a research note on Thursday. They set a “peer perform” rating for the company. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Performance

Shares of RGEN traded down $4.47 during trading hours on Thursday, reaching $146.00. 72,515 shares of the company traded hands, compared to its average volume of 657,177. The stock’s fifty day moving average is $141.59 and its 200 day moving average is $144.78. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock has a market cap of $8.18 billion, a P/E ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.23 earnings per share. Equities research analysts anticipate that Repligen will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.